GP ... nice! Maybe/hopefully an early halt for positive reasons if BoM1 data and confidence interval is replicable in BoM2?? ... that looks to be the clear "power" indication and class for apabetalone that would warrent fast approval given previous numbers and safety.

That specific indication group alone could potentially produce $2-6b in annual revenues depending on penetration and pricing. As the door opener.